Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Sells 1,135 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA trimmed its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 534,921 shares of the medical research company’s stock after selling 1,135 shares during the quarter. Thermo Fisher Scientific makes up 2.9% of Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings, making the stock its 12th biggest holding. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Thermo Fisher Scientific were worth $288,312,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. International Assets Investment Management LLC grew its stake in Thermo Fisher Scientific by 61,995.4% during the fourth quarter. International Assets Investment Management LLC now owns 1,009,671 shares of the medical research company’s stock worth $535,923,000 after purchasing an additional 1,008,045 shares during the period. Loomis Sayles & Co. L P grew its stake in Thermo Fisher Scientific by 17,046.7% during the third quarter. Loomis Sayles & Co. L P now owns 973,591 shares of the medical research company’s stock worth $492,803,000 after purchasing an additional 967,913 shares during the period. Rathbones Group PLC grew its stake in Thermo Fisher Scientific by 111.0% during the third quarter. Rathbones Group PLC now owns 568,970 shares of the medical research company’s stock worth $287,996,000 after purchasing an additional 299,338 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its stake in Thermo Fisher Scientific by 20.3% during the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 1,706,179 shares of the medical research company’s stock worth $863,617,000 after purchasing an additional 287,446 shares during the period. Finally, Wellington Management Group LLP grew its stake in Thermo Fisher Scientific by 9.8% during the third quarter. Wellington Management Group LLP now owns 3,080,687 shares of the medical research company’s stock worth $1,559,351,000 after purchasing an additional 274,464 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently commented on TMO. HSBC raised their target price on Thermo Fisher Scientific from $630.00 to $660.00 and gave the stock a “buy” rating in a research note on Wednesday, April 17th. Sanford C. Bernstein reissued a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Royal Bank of Canada raised their price objective on Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. Evercore ISI raised their price objective on Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a research note on Thursday, April 4th. Finally, Citigroup began coverage on Thermo Fisher Scientific in a research note on Monday, March 18th. They issued a “neutral” rating and a $620.00 price objective for the company. Five investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $604.69.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the business’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the sale, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the business’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the sale, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Debora L. Spar sold 164 shares of the business’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the sale, the director now owns 1,207 shares in the company, valued at $660,192.79. The disclosure for this sale can be found here. Insiders have sold a total of 50,277 shares of company stock worth $28,513,384 over the last ninety days. 0.32% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock traded up $3.59 during mid-day trading on Monday, reaching $548.37. 1,522,828 shares of the company’s stock were exchanged, compared to its average volume of 1,549,515. The business’s fifty day simple moving average is $571.30 and its 200 day simple moving average is $528.18. The firm has a market capitalization of $209.32 billion, a PE ratio of 35.49, a P/E/G ratio of 2.30 and a beta of 0.80. Thermo Fisher Scientific Inc. has a one year low of $415.60 and a one year high of $603.82. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, topping analysts’ consensus estimates of $5.64 by $0.03. The business had revenue of $10.89 billion for the quarter, compared to analyst estimates of $10.73 billion. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. Thermo Fisher Scientific’s quarterly revenue was down 4.9% compared to the same quarter last year. During the same period last year, the company posted $5.40 earnings per share. On average, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 21.51 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were paid a $0.39 dividend. The ex-dividend date was Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a dividend yield of 0.28%. Thermo Fisher Scientific’s payout ratio is presently 10.10%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.